PDE4D7 Expression Risk Stratification for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating prostate cancer often result in over-diagnosis and unnecessary treatments, leading to significant side effects and high costs, with a need for more accurate pre-surgical predictions of tumor aggressiveness to optimize patient care.
Innovation Solution
A method for risk stratification in prostate cancer using the expression level of PDE4D7, normalized against reference genes, to determine a prognostic risk score, which guides therapy selection between active surveillance and intervention, incorporating a diagnostic kit and computer program for computing risk scores.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional diagnostic methods (PSA, DRE, TRUS) are used to detect prostate cancer, then the detection coverage is high, but the false positive rate increases leading to over-diagnosis of benign conditions
Solution Approach 1:
The patent changes the diagnostic parameter from traditional clinical markers (PSA levels, physical exam findings) to molecular gene expression profiles. By measuring the expression levels of specific genes (PDE4D7, PDE4D5, PDE4D1, PDE4D2) and calculating a PDE-Index, the method achieves more precise differentiation between benign and malignant conditions, reducing false positives while maintaining high detection coverage.
2Reliability
If active intervention (surgery, radiation) is applied to all detected cases, then treatment completeness is improved, but patient quality of life deteriorates due to side effects
Solution Approach 1:
The patent applies local quality by providing personalized treatment recommendations based on individual patient risk stratification. Instead of uniform treatment for all detected cases, the PDE-Index divides patients into risk groups (very low, low, intermediate, high, very high) with corresponding tailored management strategies. This ensures aggressive treatment only for those who need it while allowing conservative management for low-risk patients, maintaining treatment completeness for malignant cases while minimizing harm to benign cases.
3Object-affected harmful factors
If active surveillance is used for low-risk patients, then quality of life is improved and costs are reduced, but the risk of disease progression must be accurately predicted
Solution Approach 1:
The patent implements feedback by using the PDE-Index as a dynamic risk assessment tool that can be measured at different time points. The gene expression profile provides continuous feedback on disease status, allowing clinicians to monitor patients under active surveillance and switch to active intervention when the PDE-Index indicates progression to higher risk categories. This feedback mechanism ensures safe active surveillance with accurate progression prediction.
4Measurement precision
If extensive lymph node dissection is performed during prostatectomy, then metastasis detection is improved, but surgical complexity and complication rates increase
Solution Approach 1:
The patent applies preliminary action by determining the PDE-Index and risk stratification before surgery. This pre-surgical molecular assessment provides advance information about the likelihood of lymph node metastasis, allowing the surgical team to plan the appropriate extent of lymph node dissection in advance. High-risk patients can undergo extensive dissection with full preparation, while low-risk patients can avoid unnecessary extensive surgery, reducing operational complexity without compromising metastasis detection for those who need it.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods are described for stratifying patient risk for patients with prostate cancer and for providing a treatment recommendation to a patient based on a phosphodiesterase 4D variant 7 (PDE4D7) risk score. A diagnostic kit and a computer program product for the analysis and determination of the PDE4D7 risk score are also described.